These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1973252)

  • 1. Prevention of hepatitis C virus infection in haemophiliacs.
    Barbara JA; Contreras M
    Lancet; 1990 Jul; 336(8706):62-3. PubMed ID: 1973252
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of hepatitis C virus infection in haemophiliacs.
    Lancet; 1990 Jun; 335(8703):1473-4. PubMed ID: 1972253
    [No Abstract]   [Full Text] [Related]  

  • 3. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs.
    Schramm W; Roggendorf M; Rommel F; Kammerer R; Pohlmann H; Rasshofer R; Gürtler L; Deinhardt F
    Blut; 1989 Oct; 59(4):390-2. PubMed ID: 2506955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of hepatitis-B immunoglobulin to clotting factor.
    Scaroni C; Cancellieri V; Carnelli V; Moroni GA; Angeli M
    Lancet; 1980 Sep; 2(8193):537-8. PubMed ID: 6105587
    [No Abstract]   [Full Text] [Related]  

  • 6. Addition of hepatitis-B immunoglobulin to clotting factors.
    Smit Sibinga CT; Das PC; Nieweg HO
    Lancet; 1980 Sep; 2(8193):537. PubMed ID: 6105586
    [No Abstract]   [Full Text] [Related]  

  • 7. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Bergman GE
    Lancet; 1995 Nov; 346(8985):1296-7. PubMed ID: 7475737
    [No Abstract]   [Full Text] [Related]  

  • 8. Wet heating for safer factor VIII concentrate?
    Kernoff PB; Miller EJ; Savidge GF; Machin SJ; Dewar MS; Preston FE
    Lancet; 1985 Sep; 2(8457):721. PubMed ID: 2863697
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of the transmission of hepatitis by clotting factor concentrates.
    Tabor E
    Scand J Haematol Suppl; 1984; 40():303-8. PubMed ID: 6433456
    [No Abstract]   [Full Text] [Related]  

  • 10. [Non-A non-B hepatitis caused by transfusing American antihemophilic globulin (factor VIII) in patients with hemophilia].
    Zhang Z; Li YH; Li XF
    Zhonghua Nei Ke Za Zhi; 1988 Feb; 27(2):82-4, 134. PubMed ID: 3141119
    [No Abstract]   [Full Text] [Related]  

  • 11. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Kessler C; Lusher J; Pierce GF; Pierce B; Koerper MA; Dickinson JC
    Lancet; 1995 Nov; 346(8985):1297-8. PubMed ID: 7475738
    [No Abstract]   [Full Text] [Related]  

  • 12. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 14. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 15. From the Centers for Disease Control and Prevention. Transmission of hepatitis C virus infection associated with home infusion therapy for hemophilia.
    JAMA; 1997 Oct; 278(13):1057-8. PubMed ID: 9315753
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of HCV infection in haemophiliacs treated with a dry-heated factor VIII concentrate.
    Kolho E; Ebeling F; Rasi V
    Thromb Haemost; 1992 Jun; 67(6):728. PubMed ID: 1509419
    [No Abstract]   [Full Text] [Related]  

  • 18. Viral safety issues: plasma-derived factor VIII.
    Berntorp E
    Ann Hematol; 1994; 68 Suppl 3():S35-6. PubMed ID: 8180256
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.
    Mannucci PM; Colombo M
    Thromb Haemost; 1989 Jun; 61(3):532-4. PubMed ID: 2508261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.